Actively Recruiting
Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-05-29
80
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In patients requiring renal replacement therapy (RRT) in the intensive care unit (ICU), continuous techniques are predominantly using due to better hemodynamic tolerance. The most employed techniques in ICU are continuous venovenous hemodiafiltration (CVVHDF) and continuous venovenous hemodialysis (CVVHD). To our knowledge, there are no prospective studies comparing the efficiency of these two techniques with the same dose of dialysis (and the same filter). In the CompEER study, we aim to compare the efficiency of CVVHD and CVVHDF on urea reduction rate in intensive care patients with acute kidney injury. The research hypothesis is that CVVHD citrate technique is as effective as CVVHDF heparin technique for urea reduction and provides prolonged and stable clearance, facilitating antibiotic management during RRT.
CONDITIONS
Official Title
Continuous Veno-venous Hemodialysis and Continuous Veno-venous Hemodiafiltration on Urea Reduction Rate in Intensive Care Patient
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients hospitalized in ICU
- Undergoing renal replacement therapy session due to acute kidney injury stage 3
- At least one of the following: pH less than 7.20, blood urea greater than 30 mM, or fluid overload uncontrolled by diuretics
- Patient has given free and informed consent or is included in an emergency situation
- Patient is affiliated with Social Security
You will not qualify if you...
- End-stage chronic kidney disease on dialysis
- Intoxication with a dialyzable toxin such as lithium
- Emergency dialysis initiation criteria: hyperkalemia greater than 6.5 mM with electrocardiographic signs
- Medical contraindication to regional citrate, including severe liver failure
- Medical contraindication to anticoagulation or heparin, including heparin-induced thrombopenia or uncontrolled bleeding
- Pregnant women, parturient, or breastfeeding patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nimes
Nîmes, France, 30029
Actively Recruiting
Research Team
C
Claire Roger, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here